News | February 19, 2009

Acusphere Changes FDA Approval Strategy for its Imagify Echo Contrast Agent

February 19, 2009 - Acusphere Inc. today submitted an amendment to its new drug application (NDA) for its ultrasound contrast agent Imagify (perflubutane polymer microspheres for injectable suspension), which is designed for the detection of coronary artery disease.

The NDA was submitted to the FDA in April 2008 and filed in June 2008. Imagify is designed to enable ultrasound to compete more effectively with nuclear stress testing, the leading procedure for detecting coronary artery disease. It is estimated that more than 10 million cardiac stress imaging procedures are done each year in the U.S., of which 6.5 million are conducted with exercise stress and 3.5 million are conducted with pharmacologic stress. If FDA accepts the submitted amendment, the Imagify indication will be limited to subsets of patients undergoing pharmacologic stress techniques.

The amended indication is focused on patients where the risk-to-benefit ratio of Imagify is more compelling than the broader indication that was originally filed. Since this is a significant amendment to the NDA for Imagify, the company said it is likely the FDA will push back the Prescription Drug User Fee Act (PDUFA) target date for their complete response letter from Feb. 28, 2009 to May 31, 2009.

The company has engaged in discussions to reduce, defer or eliminate costs to ensure that it can fund its operations beyond the anticipated PDUFA date of May 31, 2009. The company also announced today that it had completed the renegotiation of payment terms under certain intellectual property agreements. Payments totaling about $6.7 million due in 2009 will be reduced to $350,000 immediately, with another $350,000 payable upon a financing of the company, and the remainder due in 2013. In addition, the company announced last week that the Board of Directors elected not to declare a quarterly cash dividend to holders of it 6.5 percent convertible exchangeable preferred stock that was otherwise payable on March 1, 2009, saving an additional $195,000.

“These actions will carry us into June 2009 at our current burn rate and, together with discussions already in progress and other cost reduction initiatives, could allow us to explore strategic partnerships and financing alternatives following the receipt of the FDA response to our proposed amendment,” said Lawrence A. Gyenes, Acusphere’s CFO.

Acusphere is a specialty pharmaceutical company that develops new drugs and improved formulations of existing drugs using its proprietary microsphere technology. The company’s lead product candidate is Imagify. The company’s proprietary technology enables control of the porosity and size of nanoparticles and microspheres in a manner that allows them to be customized to address the delivery needs of a variety of drugs.

For more information: www.acusphere.com

Related Content

ISMRM Issues Guidelines for MRI Gadolinium Contrast Agents
News | Magnetic Resonance Imaging (MRI)| August 15, 2017
The International Society for Magnetic Resonance in Medicine (ISMRM) has provided new guidance in the use of contrast...
Oregon Tech Partners with Mindray for High-Tech Ultrasound Education
News | Ultrasound Imaging| August 04, 2017
To better prepare its ultrasound students to compete and thrive in the evolving healthcare environment, Oregon...
Carestream Shows Touch Prime Systems at Society for Vascular Ultrasound Conference
News | Cardiovascular Ultrasound| August 03, 2017
Carestream will showcase its Carestream Touch Prime and Touch Prime XE Ultrasound Systems at the Society for Vascular...
Hitachi and West Virginia University Partner to Advance Left Ventricular Mechanical Function Evaluation
News | Cardiovascular Ultrasound| July 21, 2017
Hitachi Healthcare and the West Virginia University Heart and Vascular Institute announced the formation of a new...
3-D Vascular Ultrasound Quantifies Plaque Burden to Estimate Cardiovascular Risk
News | Cardiovascular Ultrasound| July 20, 2017
July 20, 2017 — In a large, first-of-its-kind population, researchers found an experimental technique known as...
Floyd Medical Center Acquires Quartet of Toshiba Cardiac Ultrasound Systems
News | Cardiovascular Ultrasound| July 19, 2017
Floyd Medical Center in Rome, Ga., recently installed three new Aplio 500 Platinum CV ultrasound systems from Toshiba...
Cardiac CT scan showing plaque and calcification in the coronary arteries, from a Toshiba CT scanner
News | Business| July 19, 2017
July 19, 2017 — The Society of Cardiovascular Computed Tomography (SCCT) created a reimbursement fee chart for cardia
Sponsored Content | Videos | Cardiovascular Surgery| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Sponsored Content | Videos | Cardiovascular Ultrasound| July 19, 2017
This video educational session, provided in partnership with the American Society of Echocardiography (ASE), is title
Guerbet Announces Plans to Streamline Contrast Media Portfolio, gadolinium MRI contrast
News | Contrast Media| July 18, 2017
Guerbet recently announced that it will phase out sales throughout the world of two products: Hexabrix (meglumine and...
Overlay Init